Full Press Release Details
Forward-looking Statements This presentation includes
"forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the "Company") may differ from its
expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project,"
"budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts,"
"potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation,
the Company's goals and commercial plans, including the Company's expansion plans; the benefits of the Company's products and services, including the clinical evidence supporting those benefits; the market demand and acceptance for
the Company's products and services; the Company's cash runway; the Company's future performance, including its financial performance; and the Company's ability to implement its strategy. These forward-looking statements
involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause
such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop system is accepted and used by healthcare
professionals; the Company's ability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the ability of the Company to
obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the ability of the Company to identify, in-license or acquire additional technology; the ability
of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the ability of the Company to compete with other companies currently marketing or engaged in
the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in
partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's ability to generate clinical evidence of the
benefits of the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties
indicated from time to time in Company's filings with the Securities and Exchange Commission (the "SEC"), including those under "Risk Factors" therein. The Company cautions readers that the foregoing list of factors is
not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. This presentation includes preliminary financial estimates for the
fiscal year ended December 31, 2024, which reflect management's current views and may change as a result of management's final review of results and other factors, including significant business, economic and competitive risks and
uncertainties. Such preliminary financial information is subject to the finalization and closing of the accounting books and records of the Company (which have yet to be performed). In the course of preparing and finalizing these accounting books
and records, and in preparing full financial statements for the year ended December 31, 2024, the preliminary estimates for the year ended December 31, 2024 will be subject to change and the Company may identify items that will require it to make
adjustments to the Company's preliminary estimates described herein. Any such changes could be material. For these or other reasons, the preliminary financial estimates for the year ended December 31, 2024 may not ultimately be indicative of
the Company's results for such period and actual results may differ materially from those described above. No independent registered public accounting firm has audited, reviewed or compiled, examined or performed any procedures with respect to
these preliminary results, nor have they expressed any opinion or any other form of assurance on these preliminary results. These unaudited preliminary reserving estimates are presented for informational purposes only and do not purport to represent
the Company's financial condition or results of operations for any future date or period. As a result, caution should be exercised in relying on these estimates and no inferences should be drawn from these estimates regarding financial or
Leadership Team With Proven Track Record of Success Maria Sainz Dave
Castiglioni President and Chief Chief Commercial Officer Executive Officer Brett Hale Chi Nguyen Chief Administrative Vice President of Officer and Chief Office Strategy and Financial Officer Partnerships Tom Teisseyre, PhD Rafael Donnay Chief
The Portable Swoop System Serves Patients and Clinicians Where and When
They Need Brain Imaging 1 Diagnostic-quality images Broad FDA-clearance for brain with ultra-low-field MRI imaging of patients of all ages First mover with proprietary Commercially available in the technology (150+ patents) US through direct sales
channel and AI-powered software Platform technology Reimbursement in place in the US designed for multiple under existing CPT codes in both brain imaging applications hospital and office settings New ultra-low-field brain imaging Global footprint
imaging of the brain (all ages)
Sizeable and Growing U.S. Total Addressable Market Opportunity 1
Expanding TAM Through New Sites of Care & New Clinical Applications $1.5B $6B+ $16B+ 2026+ 2024+ 2025+ Beachhead Large Neuro Market Brain Health 2 5,600 emergency departments 10,700 urgent care facilities 4,000 critical care units 2,400
Multiple & Diverse Anticipated Growth Catalysts Broad Indication
& Versatile Technology Expected to Drive New Market Entrance and Adoption 2024 2025 Today US Critical Care: Continued Expansion New Outpatient Market Entry Site of Care and Use Case Drivers SITE OF CARE & USE CASE Emergency Department Entry
ACTION PMR Data (Stroke) Stroke Workflow Study EXPANSION Hospital Based Clinic Entry CARE PMR Data (Alzheimer's) Alzheimer's Workflow Study IAC Accreditation / CMS Office Site Pilot Office Based Entry India Distributor Established India CDSCO
Submission CDSCO Approval India Market Entry GEOGRAPHIC EXPANSION Europe & Asia Pacific Distributors Established 1st Full Year International Expansion 1 th 1 th th 8th Gen AI-Powered Software 9 Gen AI-Powered Software 10 Gen AI-Powered Software
Growth Catalysts De-Risked by Recent Milestones 2024 2025 Today US
Critical Care: Continued Expansion New Outpatient Market Entry Site of Care and Use Case Drivers SITE OF CARE & USE CASE Emergency Department Entry ACTION PMR Data (Stroke) Stroke Workflow Study EXPANSION Hospital Based Clinic Entry CARE PMR
Data (Alzheimer's) Alzheimer's Workflow Study IAC Accreditation / CMS Office Site Pilot Office Based Entry India Distributor Established India CDSCO Submission CDSCO Approval India Market Entry GEOGRAPHIC EXPANSION Europe & Asia Pacific
Distributors Established 1st Full Year International Expansion 1 th 1 th th 8th Gen AI-Powered Software 9 Gen AI-Powered Software 10 Gen AI-Powered Software 11 Gen AI-Powered Software TECH DEV (AI Denoising) (Faster Image Acquisition) 7 PROPERTY OF
Innovation: Fast Cadence of AI-Powered Software Releases to Drive Image
Quality Performance ... 2024 Software (8.8): Faster imaging Software (8.7): AI denoising in DWI sequence 2023 Software (8.6): DWI improvements, motion correction Software (8.5): Improved DWI image quality, intensity AI-powered Imaging uniformity,
and faster imaging. 2022 Hardware (1.9): Updates to hardware components and minimum patient weight limit Software (8.4): Fast T2: 50% faster option to the existing higher-quality T2 sequence T1 (Standard): better intraparenchymal visibility,
improved noise cancellation 2021 Software (8.3): Advanced diagnostic image reconstruction leveraging deep learning for T1, T2, and FLAIR sequences. Hardware (1.8) and Software (8.2): Automatic alignment and motion correction feature updates 2020
Image Quality Approaching High Field Hyperfine has Rapidly Accelerated
the Clinical Utility of Portable Ultra-low field MRI Illustrative Image Quality Improvements with FLAIR Contrast: pULF workhorse th th 1 First FDA Clearance 8 Generation SW Next Gen (10 ) SW Q1 2020 Launched Q1 2024 Expected 1H 2025 Proprietary
Solid Financial Fundamentals 2 Revenue and Gross Margin Cash Burn 2
Year Revenue CAGR +38% $71.0 Service Revenue 46% $20.0M 80% 43% 13% Device Revenue 30% $42.3 $15.0M $12.9M YoY $38.4 (20%) Gross Margin (%) $11.0M Growth -78% YoY $2.4M +17% Growth $10.0M (70%) $2.3M +62% $6.8M -162% (120%) $1.6M $10.5M $5.0M $8.7M
$1.5M (170%) $5.2M $0.3M $0.0M (220%) 1 2020 2021 2022 2023 2024 1 Systems Sold: 4 23 35 37 48 2022 2023 2024 Revenue Fundamentals Gross Margin Fundamentals Cash Burn Fundamentals 1 Capital placements Established global contract
manufacturing $37.6M of Cash and Cash Equivalents as of partner December 31, 2024 Recurring 3-to-5-year service & software Current cash runway expected into 2H 2026 revenue Cost efficiencies: Connected ecosystem;
cloud infrastructure Operating lean & efficient International expansion began in 2024 Scale efficiencies with volume and growing Transition to Commercial Stage organization installed base accelerated by January
2025 reorganization 1 The unaudited, preliminary 2024 financial results presented above for 2024 Revenue, Gross Margin and Cash are based on current expectations and may be adjusted as a result of, among other things, completion of annual audit
procedures. This financial information does not represent a comprehensive statement of the Company's financial results for 2024 and remains subject to the completion of financial closing procedures and internal reviews 10 PROPERTY OF
Transformation of Business Poised to Drive Growth Acceleration From
Multiple Catalysts Transformation Launched in Q4'24 Revenue Transformation From Research to Organic Commercial 2025+ Expansion Strategy Is Aggressively Pursuing New 15 Markets $12.9 13 Initial Commercialization Through
2024 driven by Research and US Critical Care Swoop System Placements $11.0 $2.4 Long Selling Processes 11 Multiple Stakeholders with Shared Decision Between Clinicians and Radiology 70% $3.4 9 Non-KCL Rev YOY Growth Growth
from New Markets Derisked by Recent Milestones $6.8 7 Neurology Offices $0.6 $2.3 23% IAC Accreditation Published Non-KCL Rev $1.6 $10.5 YOY Growth First Commercial Offices Accredited for ULF 5 First Time HYPR Presence at ASN
& NeuroNet 3 $5.3 International $4.6 CE Marked Swoop System with Latest Software Exited 2024 with 13 Active Distributors 1 India Submission underway 2 -1 2022 2023 2024 US Emergency Department Stroke Data
Presentations at RSNA and IAC 1 Device Revenue ex-KCL Service Revenue KCL Device Revenue 1 Kings College of London (KCL) completed a one-time purchase of 20 Swoop Systems with the support from the Bill and Melinda Gates Foundation 2 The unaudited,
preliminary 2024 financial results presented above for 2024 Revenue, Gross Margin and Cash are based on current expectations and may be adjusted as a result of, among other things, completion of annual audit procedures. This 11 PROPERTY OF
Appendix February 2025 Corporate Investor Deck 12 PROPERTY OF
Who is Hyperfine? First FDA-cleared, portable MR brain imaging system
with proprietary AI technology, a proven track record of innovation, broad labeling, and existing reimbursement Platform technology reshaping the care paradigm and expanding the brain imaging It feels market globally to address large, unmet
healthcare needs at multiple sites of care in hospital and office settings Revenue-generating business with attractive revenue growth and gross margin profile, strong spending discipline, and increased operating leverage 13 PROPERTY OF HYPERFINE,
A First for Brain Health Hyperfine, Inc. has a unique ultra-low-field
portable MR brain imaging system that aims to improve brain health globally. Designed to improve access, equity, and affordability for clinicians and patients Expands brain MR imaging to multiple professional healthcare settings
(critical care, emergency departments, clinics, and offices) Enables clinicians to make timely and early diagnosis of critical brain conditions Potential to reduce the burden to healthcare systems of widespread and devastating global
MRI is the Clinical Gold Standard Capacity and Availability of
Conventional MRI Compromise Access and Equity Globally High-cost and complex site requirements limit access Need for highly trained personnel constrains capacity Limited availability leads to delayed diagnosis and care Inpatient transport increases
The Portable Swoop System Serves Patients and Clinicians Where and When
They Need Brain Imaging 1 Diagnostic-quality images Broad FDA-clearance for brain with ultra-low-field MRI imaging of patients of all ages First mover with proprietary Commercially available in the technology (150+ patents) US through direct sales
channel and AI-powered software Platform technology Reimbursement in place in the US designed for multiple under existing CPT codes in both brain imaging applications hospital and office settings New ultra-low-field brain imaging Global footprint
imaging of the brain (all ages)
A New Paradigm in the Economics, Value, and Safety of Brain Imaging
Conventional MRI Swoop System CT Scanner Low Up-front Capital No Construction or Installation Required Minimal Recurring Costs No Need for Certified Operators Limited Staff Disruption Portable Soft Tissue Characterization Patient Safety: Ionizing
The Swoop System is Transforming Brain Imaging Safe for clinicians,
Blueprint for Anticipated Growth The Swoop System Designed to Expand
the Global Imaging Market to Increase Access and Equity 2026+ Brain Health 2025+ Large Neuro Market 2024+ Primary Care / Community Beachhead ED / Clinics / Offices Hospital Remote Care Critical Care Alzheimer's Pediatrics Stroke Well Brain
Sizeable and Growing U.S. Total Addressable Market Opportunity 1
Expanding TAM Through New Sites of Care & New Clinical Applications $1.5B $6B+ $16B+ 2026+ 2024+ 2025+ Beachhead Large Neuro Market Brain Health 2 5,600 emergency departments 10,700 urgent care facilities 4,000 critical care units 2,400
Multiple & Diverse Anticipated Growth Catalysts Broad Indication
& Versatile Technology Expected to Drive New Market Entrance and Adoption 2024 2025 Today US Critical Care: Continued Expansion New Outpatient Market Entry Site of Care and Use Case Drivers SITE OF CARE & USE CASE Emergency Department Entry
ACTION PMR Data (Stroke) Stroke Workflow Study EXPANSION Hospital Based Clinic Entry CARE PMR Data (Alzheimer's) Alzheimer's Workflow Study IAC Accreditation / CMS Office Site Pilot Office Based Entry India Distributor Established India CDSCO
Submission CDSCO Approval India Market Entry GEOGRAPHIC EXPANSION Europe & Asia Pacific Distributors Established 1st Full Year International Expansion 1 th 1 th th 8th Gen AI-Powered Software 9 Gen AI-Powered Software 10 Gen AI-Powered Software
Drive Adoption In Emergency Departments - Acute Ischemic Stroke Triage
Use Case Stroke Detection Sequence Optimization & AI Market Adoption ACTION-PMR, is a multi-center Software & sequence optimizations Begin placement of Swoop units in evaluation to assess the use of / updates
emergency departments and hub- Swoop system in detecting acute and-spoke stroke networks Enhance speed and accuracy for ischemic stroke as compared to stroke detection to optimize for Internal stroke advisory committee, conventional
MRI and CT time sensitive diagnosis helping adoption 100 patients enrolled in detection environments phase Data included in study published in Annals of Neurology (Aug 2024) and presented at ESNR (Sept 2024), RSNA (Dec 2024) and ISC
Drive Adoption In Neurology Office Right to Play & Office Business
Model Market Adoption Clinical Evidence IAC Accreditation standards Refine & optimize sales and Begin placement of Swoop units published November 2024 now support business model in neurology clinics include
ultra-low-field MRI, Facilitate ancillary services Drive awareness and relevance of enabling accredited medical offices (Telerad, PACS, etc.) to drive a Swoop in the Neurology to qualify for CMS reimbursement scalable office-based
solution ecosystem effective immediately Collaboration and partnerships CARE PMR clinical utility study, (e.g. Lilly, NeuroNet) presentations at AAIC, AAIC-Tokyo and CTAD Conferences. White paper on Office Use case to
IAC Standards Published in Nov 2024 Opens Office Market Opportunity
Intersocietal Accreditation Commission (IAC) 1 of 4 CMS-approved accreditation bodies Offices that get IAC accreditation are immediately eligible for CMS reimbursement New standards Incorporating Portable MRI Standards
include portable MRI technology Includes safety, training, & quality guidelines specific to POC MRI Does not require MR tech to operate POC MRI Commercially Activated Commercial pilot sites will initiate accreditation
Execution: Three Focus Areas & Spending Discipline Innovation
Innovation: Fast Cadence of AI-Powered Software Releases to Drive Image
Quality Performance ... 2024 Software (8.8): Faster imaging Software (8.7): AI denoising in DWI sequence 2023 Software (8.6): DWI improvements, motion correction AI-powered Imaging Software (8.5): Improved DWI image quality, intensity uniformity,
and faster imaging. 2022 Hardware (1.9): Updates to hardware components and minimum patient weight limit Software (8.4): Fast T2: 50% faster option to the existing higher-quality T2 sequence T1 (Standard): better intraparenchymal visibility,